[go: up one dir, main page]

CL2018001633A1 - Composiciones de benzofenonas polihidroxiladas y métodos para el tratamiento de trastornos neurodegenerativos - Google Patents

Composiciones de benzofenonas polihidroxiladas y métodos para el tratamiento de trastornos neurodegenerativos

Info

Publication number
CL2018001633A1
CL2018001633A1 CL2018001633A CL2018001633A CL2018001633A1 CL 2018001633 A1 CL2018001633 A1 CL 2018001633A1 CL 2018001633 A CL2018001633 A CL 2018001633A CL 2018001633 A CL2018001633 A CL 2018001633A CL 2018001633 A1 CL2018001633 A1 CL 2018001633A1
Authority
CL
Chile
Prior art keywords
treatment
compositions
methods
neurodegenerative disorders
polyhydroxylated
Prior art date
Application number
CL2018001633A
Other languages
English (en)
Inventor
Li-Huei Tsai
Stephen J Haggarty
Debasis Patnaik
Ping-Chieh Pao
Original Assignee
Massachusetts Inst Technology
The General Hospital Corp D/B/A Massachusetts General Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology, The General Hospital Corp D/B/A Massachusetts General Hospital filed Critical Massachusetts Inst Technology
Publication of CL2018001633A1 publication Critical patent/CL2018001633A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
    • C07C49/825—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups all hydroxy groups bound to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
    • C07C49/83—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups polycyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/20—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/32—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups
    • C07C65/34—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/017—Esters of hydroxy compounds having the esterified hydroxy group bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS DE BENZOFENONA POLIHIDROXILADA ÚTILES EN EL TRATAMIENTO DE ENFERMEDADES NEURODEGENERATIVAS, NEUROLÓGICAS, PSIQUIÁTRICA Y COGNITIVAS, EN PARTICULAR LAS ASOCIADAS CON UNA DEFICIENCIA EN LA ACTIVIDAD DE DESACETILASA HDAC1.
CL2018001633A 2015-12-17 2018-06-15 Composiciones de benzofenonas polihidroxiladas y métodos para el tratamiento de trastornos neurodegenerativos CL2018001633A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562268899P 2015-12-17 2015-12-17

Publications (1)

Publication Number Publication Date
CL2018001633A1 true CL2018001633A1 (es) 2019-01-18

Family

ID=59057697

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018001633A CL2018001633A1 (es) 2015-12-17 2018-06-15 Composiciones de benzofenonas polihidroxiladas y métodos para el tratamiento de trastornos neurodegenerativos

Country Status (13)

Country Link
US (2) US11180438B2 (es)
EP (1) EP3390347A4 (es)
JP (1) JP2019504827A (es)
KR (1) KR20180101404A (es)
CN (1) CN109071417A (es)
AU (1) AU2016369642A1 (es)
BR (1) BR112018012343A2 (es)
CA (1) CA3008854A1 (es)
CL (1) CL2018001633A1 (es)
IL (1) IL260046A (es)
MX (1) MX2018007458A (es)
RU (1) RU2018126187A (es)
WO (1) WO2017106861A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111393277B (zh) * 2020-03-15 2023-01-03 山西医科大学 4-丁基多羟基二苯甲酮类化合物衍生物及其应用
CN119193468A (zh) * 2024-09-26 2024-12-27 北京大学第三医院（北京大学第三临床医学院） 依昔苯酮在制备改善人类早期胚胎发育阻滞的药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2257272B1 (es) * 1974-01-15 1978-08-25 Pharmascience Labo
DE3877331T2 (de) * 1987-11-11 1993-05-27 Pharmascience Lab Exifon und ein wasserloesliches polymer enthaltende pharmazeutische zubereitung.
JPH02206A (ja) * 1987-11-11 1990-01-05 Fujisawa Pharmaceut Co Ltd エキシホンと水溶性高分子化合物とを含有することを特徴とする新規製剤
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
US20010047032A1 (en) * 1999-12-30 2001-11-29 Castillo Gerardo M. Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases
US6777578B2 (en) 2000-04-27 2004-08-17 Arizona Board Of Regents Hydroxyphenstatin and the prodrugs thereof
GB0724989D0 (en) * 2007-12-21 2008-01-30 Univ Sheffield Novel compounds
AU2009274571A1 (en) * 2008-07-23 2010-01-28 Massachusetts Institute Of Technology Activation of histone deacetylase 1 (HDAC1) protects against DNA damage and increases neuronal survival
CA2834548C (en) * 2011-04-28 2021-06-01 The Broad Institute, Inc. Inhibitors of histone deacetylase
PT2734510T (pt) * 2011-07-22 2019-02-13 Massachusetts Inst Technology Ativadores de histona desacetilases de classe i (hdacs) e seus usos
US9862746B2 (en) * 2013-02-15 2018-01-09 The Regents Of The University Of Michigan Compositions and methods relating to hindering DOT1L recruitment by MLL-fusion proteins
WO2015054474A1 (en) * 2013-10-10 2015-04-16 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors

Also Published As

Publication number Publication date
US20200087236A9 (en) 2020-03-19
CA3008854A1 (en) 2017-06-22
AU2016369642A1 (en) 2018-08-02
RU2018126187A (ru) 2020-01-20
KR20180101404A (ko) 2018-09-12
EP3390347A1 (en) 2018-10-24
US11180438B2 (en) 2021-11-23
JP2019504827A (ja) 2019-02-21
CN109071417A (zh) 2018-12-21
BR112018012343A2 (pt) 2018-12-04
US20180290960A1 (en) 2018-10-11
WO2017106861A1 (en) 2017-06-22
EP3390347A4 (en) 2019-07-24
US11639325B2 (en) 2023-05-02
IL260046A (en) 2018-07-31
US20210171429A1 (en) 2021-06-10
MX2018007458A (es) 2018-11-29

Similar Documents

Publication Publication Date Title
CL2018002814A1 (es) Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel.
UY34545A (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios.
CL2014003455A1 (es) Método para inhibir activación del complemento dependiente de masp-3 y, opcionalmente masp-1 y masp-2, para el tratamiento de diversas enfermedades y trastornos.
CL2018001089A1 (es) Sales de valbenazina y polimorfos de las mismas.
ECSP17018120A (es) Triazolopirazinonas como inhibidores de pde1
CU20160151A7 (es) 2-AMIN0-6-METI L-4,4a, 5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
LT3925607T (lt) Farmacinė kompozicija, skirta gydyti ligas, kurias nulemia cistinės fibrozės transmembraninio laidumo reguliatorius
MX381640B (es) Metodos y compuestos agonistas de gip.
MX2021000007A (es) Formulaciones de enzalutamida.
CL2017002719A1 (es) Imidazopirazinonas como inhibidores de pde1
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
MX388562B (es) Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
UY37038A (es) Composiciones y métodos para disminuir la expresión de tau
WO2014160871A3 (en) Methods and agents for treating alzheimer's disease
MX378940B (es) Trastornos neurodegenerativos.
AR112472A1 (es) Forma de sales cristalinas de amida de levodopa y métodos para elaborarlas y usarlas
MX2018001592A (es) Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
EA201790893A1 (ru) Способы лечения офтальмологических расстройств
DOP2016000152A (es) Quinazolin-thf-aminas como inhibidores de pde1.
UY34991A (es) Inhibidores de la beta-secretasa
MX382453B (es) Composiciones y metodos para tratar enfermedades neurodegenerativas
DOP2016000263A (es) Quinazolin-thf-aminas halogenadas como inhibidores de pde1
CL2018001633A1 (es) Composiciones de benzofenonas polihidroxiladas y métodos para el tratamiento de trastornos neurodegenerativos
CL2016002321A1 (es) Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios.